XOMA to Present November 30th at Wall Street Analyst Forum in New York
Wednesday November 16, 4:30 pm ET
BERKELEY, Calif.--(BUSINESS WIRE)--Nov. 16, 2005--XOMA Ltd. (Nasdaq:XOMA - News) announced today that David Boyle, XOMA's chief financial officer, and Bob Gundel, vice president, scientific corporate development, will present an overview of XOMA's business strategy and update of the company's current development pipeline and ongoing collaborations at the 16th Annual Wall Street Analyst Forum at the Roosevelt Hotel, Madison Avenue at 45th St., New York, NY, on Wednesday, November 30, 2005 at 11:40 am EST, followed by a breakout question and answer session at 12:20 pm.
A live webcast of the presentation can be accessed through the following link: investorcalendar.com or through XOMA's website at: xoma.com. An archived replay will be available.
About XOMA
XOMA is a pioneer and leader in the discovery, development and manufacture of therapeutic antibodies, with a therapeutic focus that includes cancer and immune diseases. XOMA has a royalty interest in RAPTIVA® (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. and Serono, SA) to treat moderate-to-severe plaque psoriasis. XOMA's discovery and development capabilities include antibody phage display, bacterial cell expression, and Human Engineering(TM) technologies, plus a fully integrated drug development infrastructure. XOMA's development collaborators include Aphton Corporation, Chiron Corporation and Lexicon Genetics Incorporated. The company pipeline also includes proprietary programs in preclinical and clinical development. For more information about XOMA's product pipeline and antibody product development capabilities and technologies, please visit XOMA's website at xoma.com. |
